**Supplementary Fig. 2. Forest plot of SVR rates with SOF/LDV regimen in the treatment of decompensated and compensated hepatitis C cirrhosis patients.** The combined SVR of SOF/LDV regimen in the treatment of patients with compensated cirrhosis was higher than that in the decompensated period: 97.5% (95% CI: 94.8–99.4) vs. 86.6% (95% CI: 85.3–88.0), *p<*0.0001. SOF, sofosbuvir; LDV, ledipasvir; RBV, ribavirin; SVR: sustained virologic response; DC, decompensated cirrhosis; CC, compensated cirrhosis.

